Results 41 to 50 of about 7,473 (181)

Darier disease—A review highlighting new insights from the Darier Disease International Task Force

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review provides a global, clinically focused overview of DD, detailing cutaneous and extracutaneous manifestations, disease classification and severity scoring. It emphasizes early recognition, multidisciplinary management and practical guidance for dermatologists to apply evidence‐based care in diverse skin phototypes. Abstract Darier disease (DD)
Sofia Labbouz, Alain Hovnanian, Grace Xiong, Dedee Frances Murrell, Simon M. Mueller, Khaled Ezzedine, Nessa Aghazadeh Mohandesi, Ahmed Salem Aldhaheri, Nissim Asayag, Eulalia Baselga, Chen Nadler, Keith Choate, Chia‐Yu Chu, John Robert Edminister, Emmanuella Guenova, Melis Gönülal, Antoni Gostynski, Ankan Gupta, Lalit Kumar Gupta, Juliette Mazereeuw‐Hautier, Wolfram Hoetzenecker, Peter Itin, Marek Jankowski, Akiharu Kubo, Haur Yueh Lee, Julia Scott Lehman, Anfisa Lepekhova, Márta Medvecz, Jemima E. Mellerio, Verena Moosbrugger‐Martinz, Amy S. Paller, Dóra Plázár, Amadeu José Rodrigues Queiróz, Josep Riera‐Monroig, Ralph Rosa, Matthias Schmuth, Maella Severino Freire, Itzhak Shabat, Jonathan Shapiro, Cory L. Simpson, Diego Soto‐García, Alexander J. Stratigos, Gianluca Abel Tadini, Takuya Takeichi, Kaushal K. Verma, Jakob D. Wikström, Alexander Zink, Michael Ziv, Alexander Navarini, Roni Pircha Dodiuk‐Gad   +49 more
wiley   +1 more source

Incidência do pênfigo vulgar ultrapassa a do pênfigo foliáceo em região endêmica para pênfigo foliáceo: análise de série histórica de 21 anos Incidence of pemphigus vulgaris exceeds that of pemphigus foliaceus in a region where pemphigus foliaceus is endemic: analysis of a 21-year historical series

Anais Brasileiros de Dermatologia, 2011
FUNDAMENTO: Há dois tipos principais de pênfigo: pênfigo vulgar e pênfigo foliáceo. Nos últimos anos, mudanças clínicas e epidemiológicas relacionadas aos pênfigos têm sido observadas.
Gilson Antonio Pereira Gonçalves, Moema Mignac Cumming Brito, Adriana Martinelli Salathiel, Thais Serraino Ferraz, Domingos Alves, Ana Maria Ferreira Roselino   +5 more
doaj   +1 more source

Expert consensus on oral management in autoimmune bullous diseases, erythema multiforme and SJS/TEN

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international Delphi study achieved expert consensus on 58 statements guiding the management of oral involvement in autoimmune bullous diseases, erythema multiforme and SJS‐TEN. The recommendations emphasize multidisciplinary care, oral hygiene and tailored topical, systemic and inpatient oral management.
Shalini Nayee, Molly Harte, Saskia Ingen‐Housz‐Oro, Milad Ameri, Sarah Walsh, Pascal Joly, Michael Ardern‐Jones, Vlaho Brailo, Marie‐Charlotte Brueggen, Christopher Bunker, Barbara Carey, Marco Carrozzo, Ser‐Ling Chua, Daniel Creamer, Donna Culton, Konstantina Delli, Marcio Diniz‐Freitas, Roni Dodiuk‐Gad, Sophie‐Myriam Dridi, Anne‐Laure Ejeil, Lars French, Krisztian Gaspar, Jon Higham, Barbara Horvarth, Esther Hullah, Sabine Jurge, Roddy McMillan, Helen McParland, Dedee Murrell, Martyn Ormond, Ana Poveda‐Gallego, Mahtab Samimi, Enno Schmidt, Martina Shephard, Tom Sollecito, Jennifer Taylor, Soner Uzun, Skaidra Valiukeviciene, Amanda Willis, Jane Setterfield   +39 more
wiley   +1 more source

Data on HLA class I/II profile in Brazilian pemphigus patients

Data in Brief, 2016
Pemphigus are blistering autoimmune diseases related with genetic and environmental factors. Here we describe HLA genotyping in pemphigus patients. First, we review the HLA class I/II data on pemphigus reported in Brazilian samples and then present the ...
Maria José Franco Brochado, Daniela Francisca Nascimento, Neifi Hassan Saloum Deghaide, Eduardo Antonio Donadi, Ana Maria Roselino   +4 more
doaj   +1 more source

CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study

Oral Diseases, EarlyView.
ABSTRACT Objective This study evaluated the CD4+ T‐cell role in mediating post‐Rituximab Pemphigus vulgaris (PV) relapse, comparing CD4+ count and CD4+/CD20+ ratio between patients who achieved remission and those who relapsed. Methods The clinical course of 27 PV patients treated with Rituximab was evaluated after a 32‐month median follow‐up. CD4+ and
Simone Liguori, Noemi Coppola, Elvira Ruoppo, Federica Canfora, Gabriele Mignogna, Ilaria Mormile, Antonia Fiore, Giuseppe Castaldo, Michele Davide Mignogna, Stefania Leuci   +9 more
wiley   +1 more source

Pemphigus Vulgaris Presented with Cheilitis

Case Reports in Dermatological Medicine, 2014
Background. Pemphigus vulgaris is an autoimmune blistering disease affecting the mucous membrane and skin. In 50 to 70% of cases, the initial manifestations of pemphigus vulgaris are oral lesions which may be followed by skin lesions.
Zaheer Abbas, Zahra Safaie Naraghi, Elham Behrangi   +2 more
doaj   +1 more source

Diagnostic Delay in Desquamative Gingivitis: An Observational Cohort Study

Oral Diseases, EarlyView.
ABSTRACT Objectives Non‐plaque‐induced gingivitis encompasses a heterogeneous group of conditions as defined in the 2017 Classification of Periodontal and Peri‐Implant Diseases and Conditions. Recognition is challenging and often leads to diagnostic delay.
Alessandra Caggiula, Francesca Romano, Elena Dentico, Fabiana Pinto, Maria Pia Lopez‐Jornet, Massimo Petruzzi   +5 more
wiley   +1 more source

Pemphigus vulgaris [PDF]

BMJ Case Reports, 2020
Vijayendranath, Nayak, Raghavendra, Kini, Prasanna Kumar, Rao, Ujwala, Shetty   +3 more
openaire   +2 more sources

Long‐Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trial Interim Analysis

Journal of the Peripheral Nervous System, Volume 31, Issue 3, September 2026.
ABSTRACT Background and Aims In ADHERE, subcutaneous efgartigimod PH20 (1000 mg once weekly) was effective and well tolerated in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). ADHERE+ is an open‐label extension of ADHERE assessing long‐term safety and efficacy. Methods Eligible participants from ADHERE run‐in period
Jeffrey A. Allen, Geoffrey Istas, Satoshi Kuwabara, Trevor Mole, Luis Querol, Simon Rinaldi, Mark Stettner, Benjamin Van Hoorick, Richard A. Lewis   +8 more
wiley   +1 more source

A Case Report of a Patient With Recalcitrant Pemphigus Vulgaris Treated With Rituximab

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Pemphigus vulgaris may demonstrate differential treatment responses across disease sites. In this case, cutaneous lesions responded to high‐dose corticosteroids, whereas refractory oral disease required rituximab to achieve remission, highlighting the need for individualized, multimodal therapy to achieve sustained disease control.
Mahlatse Cordelia Kgokolo, Lesedi Makgwethele Nevondo, Michaela Beetge, Razia A. G. Khammissa   +3 more
wiley   +1 more source